Frataxin deficiency unveils cell-context dependent actions of insulin-like growth factor i on neurons

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Franco, Carolina ^a   Fernández, Silvia ^a   Torres Alemán, Ignacio ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

Frataxin; Friedreich's ataxia; Insulin like growth factor 1; Neuroprotection

Indexed keywords

FRATAXIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; CONTROLLED STUDY; FRATAXIN DEFICIENCY; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ANIMALS; ASTROCYTES; CELLS, CULTURED; FEMALE; FRIEDREICH ATAXIA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; IRON-BINDING PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION;

MUS; MUS MUSCULUS;

EID: 84867019859     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-51     Document Type: Article

References (30)

1. The many faces of insulin-like peptide signalling in the brain. Fernandez AM, Torres-Aleman I, Nat Rev Neurosci 2012 13 225 239 10.1038/nrn3209 22430016
2. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. Carro E, Trejo JL, Busiguina S, Torres-Aleman I, J Neurosci 2001 21 5678 5684 11466439 (Pubitemid 32692166)
3. Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia. Fernandez AM, de la Vega AG, Torres-Aleman I, Proc Natl Acad Sci USA 1998 95 1253 1258 10.1073/pnas.95.3.1253 9448318 (Pubitemid 28124945)
4. Insulin-like growth factor-I improves cerebellar dysfunction but does not prevent cerebellar neurodegeneration in the calcium channel mutant mouse, leaner. Nahm SS, Frank TC, Browning MD, Sepulvado JM, Hiney JK, Abbott LC, Neurobiol Dis 2003 14 157 165 10.1016/S0969-9961(03)00106-2 14572439 (Pubitemid 37311281)
5. GDNF and IGF-I trophic factors delay hereditary Purkinje cell degeneration and the progression of gait ataxia. Tolbert DL, Clark BR, Exp Neurol 2003 183 205 219 10.1016/S0014-4886(03)00172-9 12957504 (Pubitemid 37075871)
6. AF4 Is a Critical Regulator of the IGF-1 Signaling Pathway during Purkinje Cell Development. Bitoun E, Finelli MJ, Oliver PL, Lee S, Davies KE, J Neurosci 2009 29 15366 15374 10.1523/JNEUROSCI.5188-09.2009 20007461
7. Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: an open label clinical trial. Arpa J, Sanz-Gallego I, Medina-Baez J, Portela LV, Jardim LB, Torres-Aleman I, et al. Mov Disord 2011 26 358 359 10.1002/mds.23423 20960476
8. The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Gatchel JR, Watase K, Thaller C, Carson JP, Jafar-Nejad P, Shaw C, et al. Proc Natl Acad Sci USA 2008 105 1291 1296 10.1073/pnas.0711257105 18216249 (Pubitemid 351397046)
9. Ataxia-telangiectasia and cellular responses to DNA damage. Meyn MS, Cancer Res 1995 55 5991 6001 8521380
10. Puccio H+: Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Sp S, Hum Mol Genet 2010 19 103 R110 10.1093/hmg/ddq165 20413654
11. Age to survive: DNA damage and aging. Br S, Garinis GA, Hoeijmakers JHJ, Trends Genet 2008 24 77 85 10.1016/j.tig.2007.11.004 18192065
12. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Shahrabani-Gargir L, Pandita TK, Werner H, Endocrinology 2004 145 5679 5687 10.1210/en.2004-0613 15345673 (Pubitemid 39564610)
13. Neurodegeneration Is Associated to Changes in Serum Insulin-like Growth Factors. Busiguina S, Fernandez AM, Barrios V, Clark R, Tolbert DL, Berciano J, et al. Neurobiol Dis 2000 7 657 665 10.1006/nbdi.2000.0311 11114263 (Pubitemid 32044289)
14. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, Rai M, et al. Hum Mol Genet 2009 18 2452 2461 10.1093/hmg/ddp183 19376812
15. Insulin-like growth factor I and impaired glucose tolerance. Dunger D, Yuen K, Ong K, Horm Res 2004 62 Suppl 1 101 107 15761241 (Pubitemid 40529158)
16. Insulin-like growth factor I treatment for cerebellar ataxia: addressing a common pathway in the pathological cascade? Fernandez AM, Carro EM, Lopez-Lopez C, Torres-Aleman I, Brain Res Brain Res Rev 2005 50 134 141 15950289 (Pubitemid 41607521)
17. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Nishijima T, Piriz J, Duflot S, Fernandez AM, Gaitan G, Gomez-Pinedo U, et al. Neuron 2010 67 834 846 10.1016/j.neuron.2010.08.007 20826314
18. Low Doses of Insulin-Like Growth Factor I Improve Insulin Resistance, Lipid Metabolism, and Oxidative Damage in Aging Rats. Garcia-Fernandez M, Delgado G, Puche JE, Gonzalez-Baron S, Castilla Cortazar I, Endocrinology 2008 149 2433 2442 10.1210/en.2007-1190 18187555 (Pubitemid 351574496)
19. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. Bijur GN, Jope RS, J Neurochem 2003 87 1427 1435 10.1046/j.1471-4159.2003.02113.x 14713298 (Pubitemid 38020576)
20. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, LeMeur M, et al. Hum Mol Genet 2000 9 1219 1226 10.1093/hmg/9.8.1219 10767347 (Pubitemid 30248608)
21. Use of MTT colorimetric assay to measure cell activation. Gerlier D, Thomasset N, J Immunol Methods 1986 94 57 63 10.1016/0022-1759(86)90215-2 3782817 (Pubitemid 17186343)
22. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, Hughes S, et al. Genomics 2006 88 580 590 10.1016/j.ygeno.2006.06.015 16919418 (Pubitemid 44540244)
23. Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia. Rufini A, Fortuni S, Arcuri G, Condo I, Serio D, Incani O, et al. Hum Mol Genet 2011 20 1253 1261 10.1093/hmg/ddq566 21216878
24. Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Trejo JL, Piriz J, Llorens-Martin MV, Fernandez AM, Bolos M, LeRoith D, et al. Mol Psychiatry 2007 12 1118 1128 10.1038/sj.mp. 4002076 17848918 (Pubitemid 350191366)
25. Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I, J Neurosci 2007 27 8745 8756 10.1523/JNEUROSCI.1002-07.2007 17699657 (Pubitemid 47292768)
26. Insulin-like growth factor I potentiates kainate receptors through a phosphatidylinositol 3-kinase dependent pathway. Gonzalez dl V, Buno W, Pons S, Garcia-Calderat MS, Garcia-Galloway E, Torres-Aleman I, Neuroreport 2001 12 1293 1296 10.1097/00001756-200105080-00047 11338209 (Pubitemid 32374761)
27. Expression and activities of cyclins and cyclin-dependent kinases in developing rat ventricular myocytes. Brooks G, Poolman RA, McGill CJ, Li JM, J Mol Cell Cardiol 1997 29 2261 2271 10.1006/jmcc.1997.0471 9281457 (Pubitemid 27348535)
28. Insulin-like growth factor I is required for vessel remodeling in the adult brain. Lopez-Lopez C, LeRoith D, Torres-Aleman I, Proc Natl Acad Sci USA 2004 101 9833 9838 10.1073/pnas.0400337101 15210967 (Pubitemid 38869322)
29. Insulin-like Growth Factor-I Stimulates Dephosphorylation of Ikappa B through the Serine Phosphatase Calcineurin (Protein Phosphatase 2B). Pons S, Torres-Aleman I, J Biol Chem 2000 275 38620 38625 10973957 (Pubitemid 32009191)
30. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)